Cargando…

Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients

Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make t...

Descripción completa

Detalles Bibliográficos
Autores principales: Reidenberg, Bruce E., Wanner, Christoph, Polsky, Bruce, Castanheira, Mariana, Shelip, Alla, Stalleicken, Dirk, Pfaffle, Antony E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978892/
https://www.ncbi.nlm.nih.gov/pubmed/29214504
http://dx.doi.org/10.1007/s10096-017-3157-7
_version_ 1783327576916230144
author Reidenberg, Bruce E.
Wanner, Christoph
Polsky, Bruce
Castanheira, Mariana
Shelip, Alla
Stalleicken, Dirk
Pfaffle, Antony E.
author_facet Reidenberg, Bruce E.
Wanner, Christoph
Polsky, Bruce
Castanheira, Mariana
Shelip, Alla
Stalleicken, Dirk
Pfaffle, Antony E.
author_sort Reidenberg, Bruce E.
collection PubMed
description Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls.
format Online
Article
Text
id pubmed-5978892
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59788922018-06-21 Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients Reidenberg, Bruce E. Wanner, Christoph Polsky, Bruce Castanheira, Mariana Shelip, Alla Stalleicken, Dirk Pfaffle, Antony E. Eur J Clin Microbiol Infect Dis Original Article Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimicrobials with specific mechanisms of action make this an appropriate target for applying a nonspecific antimicrobial therapeutic. Taurolidine hydrolyzes into two antimicrobial moieties, formaldehyde and methylene glycol, which react with microbial surfaces. Neutrolin® (taurolidine, heparin, calcium citrate) was recently introduced in Germany as an antimicrobial catheter lock solution. This postmarketing experience collected data on 201 patients at 20 centers from January 2014 through September 2016. Likely CRBSI was observed in 13 episodes in 47,118 days (0.2759 per 1000 days [0.1468, 0.4718]). Thrombosed catheter was observed in seven catheters in 47,118 days (0.1486 per 1000 days [0.0595, 0.3061]). No adverse drug reactions that led to the discontinuation of Neutrolin® use were reported. Two patients experienced occasional transient dysgeusia. Neutrolin®, when used in conjunction with guideline-based catheter care, showed reduction in the rate of both CRBSI and catheter thrombosis relative to recent historical controls. Springer Berlin Heidelberg 2017-12-06 2018 /pmc/articles/PMC5978892/ /pubmed/29214504 http://dx.doi.org/10.1007/s10096-017-3157-7 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Reidenberg, Bruce E.
Wanner, Christoph
Polsky, Bruce
Castanheira, Mariana
Shelip, Alla
Stalleicken, Dirk
Pfaffle, Antony E.
Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
title Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
title_full Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
title_fullStr Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
title_full_unstemmed Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
title_short Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
title_sort postmarketing experience with neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978892/
https://www.ncbi.nlm.nih.gov/pubmed/29214504
http://dx.doi.org/10.1007/s10096-017-3157-7
work_keys_str_mv AT reidenbergbrucee postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients
AT wannerchristoph postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients
AT polskybruce postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients
AT castanheiramariana postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients
AT shelipalla postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients
AT stalleickendirk postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients
AT pfaffleantonye postmarketingexperiencewithneutrolintaurolidineheparincalciumcitratecatheterlocksolutioninhemodialysispatients